DDInter1814 DDInter1435
An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Tioguanine {u} (Compound) resembles {v} (Compound) Adenine
Tioguanine {u} (Compound) treats {v} (Disease) hematologic cancer
Tioguanine {u} (Compound) binds {v} (Gene) IMPDH2
Tioguanine {u} (Compound) causes {v} (Side Effect) Portal hypertension
Tioguanine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sparfloxacin
Tioguanine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Tioguanine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Efalizumab
Tioguanine {u} may lead to a major life threatening interaction when taken with {v} Deferiprone
Tioguanine {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Tioguanine {u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mercaptopurine
Tioguanine (Compound) resembles Adenine (Compound)
Tioguanine (Compound) treats hematologic cancer (Disease)
Tioguanine (Compound) binds IMPDH2 (Gene)
Tioguanine (Compound) causes Portal hypertension (Side Effect)
Tioguanine may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Influenza A virus A/California/7/2009 (H1N1)-like antigen (propiolactone inactivated)
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab
Tioguanine may lead to a major life threatening interaction when taken with Deferiprone
Tioguanine may lead to a major life threatening interaction when taken with Cladribine
Tioguanine (Compound) resembles Mercaptopurine (Compound) and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine